S
Sonoma Biotherapeutics
Best-in-class regulatory T cell therapy, delivering long-lasting, highly effective, curative treatments across a spectrum of autoimmune and degenerative diseases
About Sonoma Biotherapeutics
Sonoma Bio is a biotechnology startup that operates in the healthcare sector, specifically in the field of autoimmune and inflammatory disease treatment. The company's primary focus is on developing living cell therapies that aim to restore balance to the immune system and potentially cure autoimmune diseases. This innovative approach utilizes the body's own immune response regulators to correct an overactive immune system, a common issue in autoimmune conditions.
Sonoma Bio's business model is centered around the research and development of these therapies. The company leverages the extensive research of its founders and a team of dedicated scientists to pioneer new treatments in Treg biology and cell therapy. The company's revenue is likely generated through partnerships with healthcare providers and institutions, as well as potential future sales of their developed therapies.
The company's target market includes patients suffering from autoimmune diseases and their care partners. Sonoma Bio is driven by a mission to not only find a cure for these diseases but also to significantly improve the quality of life for those affected by them.
The company's approach is rooted in scientific knowledge and collaboration, balancing these with a capable team that can execute their vision. They are committed to meeting the needs of patients and care partners, and their work is firmly grounded in science.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Nov 2025 | $300K | — | ScaleReady | ↗ |
| SERIES BOther financing | Aug 2021 | $265M | $1.1B | 8VC · Mirae Asset Capital · Frazier Healthcare Partners · Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for Sonoma Biotherapeutics is 7.5K monthly website visits, up 92.3% over the last three months. Sonoma Biotherapeutics's team declined 43.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sonoma Biotherapeutics in the South San Francisco ecosystem
The Sonoma Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
ScaleReady
Series A22 investors entered at this stage
8VC
Lyell Immunopharma
ARCH Venture Partners
Milky Way Ventures
JDRF T1D Fund
Alexandria Venture Investments
Lilly Asia Ventures
Lifeforce Capital
Octagon Capital Partners
Ally Bridge Group
Mirae Asset Capital
Frazier Healthcare PartnersJanus Henderson Investors
Vertex Ventures HC- TCTimefolio Capital
Fidelity Investments
Casdin Capital
Osage University Partners- APArrowMark Partners
Avidity Partners
Deep Track Capital- PCPiper Heartland Healthcare Capital
Other known investors2 additional known investors
University of California, San Francisco
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sonoma Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sonoma Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









